{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:13:20Z","timestamp":1778566400347,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"DOI":"10.7759\/cureus.108691","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:29:28Z","timestamp":1778563768000},"source":"Crossref","is-referenced-by-count":0,"title":["CRISPR-Cas9-Mediated Gene Editing in Hematological Disorders: Advancing Translational and Clinical Applications"],"prefix":"10.7759","author":[{"given":"Abhay","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishikesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradip","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallu","family":"Mallikarjuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Sambhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1530\/ey.18.14.4","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"18","author":"Frangoul H","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, et al.. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. ESPE Yearb Paediatr Endocrinol. 2021, 18:14.4. 10.1530\/ey.18.14.4","journal-title":"ESPE Yearb Paediatr Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen S","year":"2018","unstructured":"Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018, 55:141-9. 10.1053\/j.seminhematol.2018.04.002","journal-title":"Semin Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.014","article-title":"Targeting a pre-existing anti-transgene T cell response for effective gene therapy of MPS-I in the mouse model of the disease","volume":"27","author":"Squeri G","year":"2019","unstructured":"Squeri G, Passerini L, Ferro F, et al.. Targeting a pre-existing anti-transgene T cell response for effective gene therapy of MPS-I in the mouse model of the disease. Mol Ther. 2019, 27:1215-27. 10.1016\/j.ymthe.2019.04.014","journal-title":"Mol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O'Brien K","year":"2020","unstructured":"O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020, 21:585-606. 10.1038\/s41580-020-0251-y","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.022","article-title":"Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease","volume":"21","author":"Uchida N","year":"2021","unstructured":"Uchida N, Drysdale CM, Nassehi T, et al.. Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol Ther Methods Clin Dev. 2021, 21:121-32. 10.1016\/j.omtm.2021.02.022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas CA","year":"2018","unstructured":"Vakulskas CA, Dever DP, Rettig GR, et al.. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018, 24:1216-24. 10.1038\/s41591-018-0137-0","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth TL","year":"2018","unstructured":"Roth TL, Puig-Saus C, Yu R, et al.. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018, 559:405-9. 10.1038\/s41586-018-0326-5","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem J","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, et al.. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017, 543:113-7. 10.1038\/nature21405","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore JD","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al.. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021, 385:493-502. 10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer EA","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, et al.. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020, 367:7365. 10.1126\/science.aba7365","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela XM","year":"2019","unstructured":"Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019, 70:273-88. 10.1146\/annurev-med-012017-043332","journal-title":"Annu Rev Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa M","year":"2024","unstructured":"Pacesa M, Pelea O, Jinek M. Past, present, and future of CRISPR genome editing technologies. Cell. 2024, 187:1076-100. 10.1016\/j.cell.2024.01.042","journal-title":"Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru K","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al.. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021, 593:429-34. 10.1038\/s41586-021-03534-y","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu PD","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014, 157:1262-78. 10.1016\/j.cell.2014.05.010","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna JA","year":"2014","unstructured":"Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014, 346:1258096. 10.1126\/science.1258096","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek M","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012, 337:816-21. 10.1126\/science.1225829","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban MD","year":"2015","unstructured":"Hoban MD, Cost GJ, Mendel MC, et al.. Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells. Blood. 2015, 125:2597-604. 10.1182\/blood-2014-12-615948","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3480","article-title":"CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease","volume":"9","author":"De Ravin SS","year":"2017","unstructured":"De Ravin SS, Li L, Wu X, et al.. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med. 2017, 9:3480. 10.1126\/scitranslmed.aah3480","journal-title":"Sci Transl Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul H","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, et al.. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021, 384:252-60. 10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190139","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"142","author":"Frangoul H","year":"2023","unstructured":"Frangoul H, Locatelli F, Sharma A, et al.. Exagamglogene autotemcel for severe sickle cell disease. Blood. 2023, 142:1052. 10.1182\/blood-2023-190139","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.029","article-title":"How to boost the impact of scientific conferences","volume":"182","author":"Morrison M","year":"2020","unstructured":"Morrison M, Merlo K, Woessner Z. How to boost the impact of scientific conferences. Cell. 2020, 182:1067-71. 10.1016\/j.cell.2020.07.029","journal-title":"Cell"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees HA","year":"2018","unstructured":"Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018, 19:770-88. 10.1038\/s41576-018-0059-1","journal-title":"Nat Rev Genet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver MC","year":"2015","unstructured":"Canver MC, Smith EC, Sher F, et al.. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015, 527:192-7. 10.1038\/nature15521","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler EA","year":"2016","unstructured":"Traxler EA, Yao Y, Wang YD, et al.. A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016, 22:987-90. 10.1038\/nm.4170","journal-title":"Nat Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.05.006","article-title":"One-vector system for multiplexed CRISPR\/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors","volume":"12","author":"Schiwon M","year":"2018","unstructured":"Schiwon M, Ehrke-Schulz E, Oswald A, Bergmann T, Michler T, Protzer U, Ehrhardt A. One-vector system for multiplexed CRISPR\/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors. Mol Ther Nucleic Acids. 2018, 12:242-53. 10.1016\/j.omtn.2018.05.006","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.11.036","article-title":"Restoration of visual function by enhancing conduction in regenerated axons","volume":"164","author":"Bei F","year":"2016","unstructured":"Bei F, Lee HH, Liu X, et al.. Restoration of visual function by enhancing conduction in regenerated axons. Cell. 2016, 164:219-32. 10.1016\/j.cell.2015.11.036","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu X","year":"2017","unstructured":"Liu X, Zhang Y, Cheng C, et al.. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017, 27:154-7. 10.1038\/cr.2016.142","journal-title":"Cell Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD-1 inhibition","volume":"23","author":"Ren J","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD-1 inhibition. Clin Cancer Res. 2017, 23:2255-66. 10.1158\/1078-0432.CCR-16-1300","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot L","year":"2015","unstructured":"Poirot L, Philip B, Schiffer-Mannioui C, et al.. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Res. 2015, 75:3853-64. 10.1158\/0008-5472.CAN-14-3321","journal-title":"Cancer Res"},{"key":"ref30","unstructured":"Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. (2018). Accessed. March 5, 2026: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-and-clinical-aspects-gene-...."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2017.11.006","article-title":"Engineering the delivery system for CRISPR-based genome editing","volume":"36","author":"Glass Z","year":"2018","unstructured":"Glass Z, Lee M, Li Y, Xu Q. Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol. 2018, 36:173-85. 10.1016\/j.tibtech.2017.11.006","journal-title":"Trends Biotechnol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu E","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, et al.. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020, 382:545-53. 10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"key":"ref33","unstructured":"WMA declaration of Helsinki - ethical principles for medical research involving human participants. (2024). Accessed. March 5, 2026: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso RT","year":"2017","unstructured":"Manguso RT, Pope HW, Zimmer MD, et al.. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017, 547:413-8. 10.1038\/nature23270","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2016.28","article-title":"Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases","volume":"17","author":"Tsai SQ","year":"2016","unstructured":"Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet. 2016, 17:300-12. 10.1038\/nrg.2016.28","journal-title":"Nat Rev Genet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.03.006","article-title":"Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways","volume":"151","author":"Fumarola C","year":"2018","unstructured":"Fumarola C, Petronini PG, Alfieri R. Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways. Biochem Pharmacol. 2018, 151:114-25. 10.1016\/j.bcp.2018.03.006","journal-title":"Biochem Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai SQ","year":"2015","unstructured":"Tsai SQ, Zheng Z, Nguyen NT, et al.. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015, 33:187-97. 10.1038\/nbt.3117","journal-title":"Nat Biotechnol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3101","article-title":"Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases","volume":"33","author":"Frock RL","year":"2015","unstructured":"Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol. 2015, 33:179-86. 10.1038\/nbt.3101","journal-title":"Nat Biotechnol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker IM","year":"2016","unstructured":"Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016, 351:84-8. 10.1126\/science.aad5227","journal-title":"Science"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2016.04.013","article-title":"Induced pluripotent stem cells meet genome editing","volume":"18","author":"Hockemeyer D","year":"2016","unstructured":"Hockemeyer D, Jaenisch R. Induced pluripotent stem cells meet genome editing. Cell Stem Cell. 2016, 18:573-86. 10.1016\/j.stem.2016.04.013","journal-title":"Cell Stem Cell"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465966-crispr-cas9-mediated-gene-editing-in-hematological-disorders-advancing-translational-and-clinical-applications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:29:30Z","timestamp":1778563770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465966-crispr-cas9-mediated-gene-editing-in-hematological-disorders-advancing-translational-and-clinical-applications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.108691","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}